Vanderbilt University Medical Center
Dementia is one of the major causes of disability and among older adults globally, with 6.7 million Americans living with Alzheimer's disease. Depression is common in people with cognitive and memory problems. Depression in the elderly increases the risk of disability, medical comorbidity, cognitive impairment, and death. Patients with depression are at an increased risk of worsening cognition. Further, patients with depression are traditionally excluded from therapeutic trials in Alzheimer's Disease and other dementias. Current medications to treat depression in patients with dementia haven't been helpful. Effective approaches to treating depression in dementia are necessary. Ketamine has been studied extensively for the treatment of depression. It produces a rapid antidepressant effect with improvement of depressive symptoms reported 2 hours after infusion that continues for several days. Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia and reduce depression burden and improve quality of life and function. As patients with depression are likely unable to receive disease modifying therapies for Alzheimer's Disease (lecanemab or donanemab) rapid improvement of depressive symptoms with ketamine could represent treatment that allows them to be able to receive these therapies faster. This proposal, will examine the safety, tolerability and feasibility of administering IV ketamine for the treatment of depression in participants with Alzheimer's Disease as well as obtain preliminary data regarding the treatment benefit.
Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia, but will also reduce neuropsychiatric symptom burden and improve quality of life and function. As patients with moderate to severe depression are likely unable to receive lecanemab or donanemab for treatment of AD, rapid improvement of depress…
Inclusion Criteria: 1. Age \>= 60 years; 2. Diagnosis for major depressive disorder meeting DSM5 criteria based on clinical assessment by the study clinician 3. MADRS score \>= 18 4. Clinical diagnosis of MCI or mild dementia due to Alzheimer's Disease 5. Quick Dementia Rating System (QDRS) 2-12 6. Montreal Cognitive Assessment (MoCA) \> 14 at screening 7. Positive AD biomarker (CSF p-tau181/Aβ42, tau/Aβ42, Aβ42/40, amyloid PET, Tau PET or clinical plasma assays such (p-tau 217 or 181), consistent with AD criteria 8. Stable antidepressant medication regimen for at least 4 weeks prior to the s…
Ketamine will be infused over 40 min twice weekly for two weeks. Ketamine will be calculated as 0.5mg/kg.
Active placebo (midazolam) will be infused over 40 min twice weekly for two weeks. Active placebo (midazolam) dose will be calculated as 0.02mg/kg.